Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.48 |
| ▸ | ICMT | O60725 | 1/20 | 0.41 |
| ▸ | EIF4E | P06730 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | DCK | P27707 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 8/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10120512 | 0.88 | AR (0.46) | GPR119EIF4EMKNK1MKNK2DCK | |
| SCHEMBL15381346 | 0.85 | TRPA1 (0.44) | GPR119ICMTDCKSLC22A12TRPA1 | |
| SCHEMBL10134278 | 0.82 | GPR119 (0.48) | GPR119ICMTDCKSLC22A12TRPA1 | |
| SCHEMBL10120569 | 0.79 | EIF4E (0.51) | GPR119EIF4EMKNK1MKNK2 | |
| SCHEMBL524718 | 0.79 | SLC6A9 (0.45) | GPR119ICMTEIF4EMKNK1MKNK2 | |
| SCHEMBL10105771 | 0.78 | GPR119 (0.43) | GPR119SLC22A12 | |
| SCHEMBL10105803 | 0.77 | TRPA1 (0.36) | GPR119TRPA1 | |
| SCHEMBL7029209 | 0.77 | AR (0.48) | GPR119ICMTSLC6A9KCNH2 | |
| SCHEMBL10105796 | 0.76 | DCK (0.44) | GPR119DCKSLC22A12 | |
| SCHEMBL10105798 | 0.76 | GPR119 (0.51) | GPR119SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, BDKRB2, GLP1R | GPR119 1/4885ICMT 4343/4885EIF4E 3412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.